MedCity News September 10, 2024
Roivant Sciences subsidiary Pulmovant is on track for a Phase 2 test of mosliciguat as a treatment for pulmonary hypertension associated with interstitial lung disease. The inhaled drug offers a different mechanism of action and less burdensome dosing compared to United Therapeutics’ blockbuster PH-ILD drug, Tyvaso.
Roivant Sciences is expanding its scope to the lungs, unveiling a new subsidiary whose main asset, licensed from Bayer, offers the potential to bring patients a novel treatment for a rare type of pulmonary hypertension currently served by only one FDA-approved therapy.
The new Roivant company revealed Tuesday is named Pulmovant. Roivant, whose business model involves in-licensing drugs shelved by big pharmaceutical companies and then forming subsidiaries it calls “Vants” to advance their development,...
Today's Sponsors
Today's Sponsor